Monotherapy for Pediatric Focal Epilepsy: Levetiracetam vs. Carbamazepine, Which is the Better Option?

Epilepsy is a chronic neurological disorder that affects approximately 1% of the global population, including 1 in 200 children. Managing pediatric epilepsy often relies on anticonvulsant monotherapy, but the optimal drug choice remains a topic of debate. Levetiracetam (LEV) and carbamazepine (CBZ) are both common treatments, each with specific benefits and distinct side effect profiles.
This study analyzed the efficacy and safety of LEV and CBZ in children and adolescents with focal epilepsy, aiming to provide clearer therapeutic guidance.